Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Key facts
- Who runs it
- Timothy Yu
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 10 people, planned
- Started
- Aug 2026
- Expected to end
- Dec 2036
- Type of study
- Interventional
- Treatments tested
- Antisense oligonucleotide targeting the ATM gene
- Record updated
- 28 May 2026
Who can take part
- Age
- 0 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Other criteria
- INCLUSION/EXCLUSION CRITERIA:
- Who can take part:
- People with classic A-T confirmed by genetic testing
- Must have a specific ATM gene change (c.7865C>T)
- Must also have another ATM change that causes A-T; Who cannot take part:; People with health problems that make lumbar puncture unsafe:
- Blood clotting or bleeding problems
- Brain conditions raising pressure inside the head
- Serious heart or breathing problems
- Infection near the lower back; Other things doctors will check:
- Overall health and stability
- Any medicines that might cause problems
- Past difficulties with lumbar punctures
- Any other safety concerns
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 17 years old?
Where in United States
- Boston Children's HospitalBoston, United StatesContact: Arya NewingtonTaking people
About the trial
What the trial wants to find out
This project aims to evaluate the safety and efficacy of precision genetic therapy for patients with Ataxia-telangiectasia (A-T), a rare neurodegenerative disease caused by mutations in the ATM gene. The investigators will conduct a clinical trial to study the safety and efficacy of intrathecal administration of atipeksen, a targeted genetic therapy that restores ATM gene function in A-T individuals bearing the recurrent ATM c.7865C>T variant. The aim of this study is to delay or forestall progression of neurologic symptoms in A-T and improving quality of life. Success will provide an empirical foundation for advancing additional precision genetic therapies for A-T and other neurodegenerative conditions.
The group in the trial
- Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia - TelangiectasiaTreatment being tested
Individuals with genetically confirmed, classic ataxia telangiectasia with at least one copy of the ASO-amenable ATM variant NM\_000051.3:c.7865C\>T;p.Ala2622Val, will receive the ASO at the same dose.
Treatment: Antisense oligonucleotide targeting the ATM gene
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia-Telangiectasia
- Criteria questions
- Built from NCT07215416, who can take part
- Record updated
- 28 May 2026